FIELD: medicine.
SUBSTANCE: group of inventions relates to the use of a faecal microbiota composition for preventing and/or reducing treatment-induced inflammation in a patient with cancer and/or haematological disease and a method for preventing and/or reducing treatment-induced inflammation in a patient suffering cancer and/or haematological disease. Use of the faecal microbiota composition for preventing and/or reducing treatment-induced inflammation in a patient suffering cancer and/or haematological disease, wherein the faecal microbiota composition is prepared by a method comprising the following steps: (i) collecting a stool sample and placing it in anaerobic conditions for maximum of 5 minutes after collection; (ii) still under anaerobic conditions, mixing the sample with an aqueous saline solution comprising a cryoprotectant and/or bulking agent; and (iii) filtering the diluted sample, wherein the treatment-induced inflammation is caused by anti-cancer therapy and/or haemopoietic stem cell transplantation (HSCT), where the proportion of some or all of following 15 genera increases compared to the pre-faecal FMT microbiota transfer level: Blautia, Faecalibacterium, Alistipes, Eubacterium, Bifidobacterium, Ruminococcus, Clostridium, Coprococcus, Odoribacter, Roseburia, Holdemanella, Anaerostipes, Oscillibacter, Subdoligranulum and Butyrivibrio, and wherein faecal microbiota transfer (FMT) with said faecal microbiota composition leads to a decrease in the level of neopterin in the intestine and/or a decrease in the level of serum CRP and/or serum ferritin. Method of preventing and/or reducing treatment-induced inflammation in a patient suffering cancer and/or haematological disease, comprising administering a faecal microbiota composition, wherein the faecal microbiota composition is obtained using the method described above.
EFFECT: group of inventions described above enables to obtain a faecal microbiota composition using a reliable and reproducible process which complies with good manufacturing practice (GMP) and meets modern pharmaceutical requirements in terms of safety and efficacy, the obtained composition has improved and optimal anti-inflammatory ability.
14 cl, 9 dwg, 14 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
METHODS FOR IMPROVING BLOCKADE THERAPY OF IMMUNE CHECKPOINTS THROUGH MICROBIOME MODULATION | 2017 |
|
RU2793582C2 |
METHOD OF PREVENTION AND/OR TREATMENT OF INSULIN RESISTANCE | 2012 |
|
RU2613322C2 |
PHARMACEUTICAL COMPOSITION CONTAINING NICOTINIC ACID AND/OR NICOTINAMIDE AND/OR TRYPTOPHAN FOR POSITIVELY INFLUENCING THE INTESTINAL MICROBIOTA | 2013 |
|
RU2657797C2 |
USE OF MICROBIAL COMMUNITIES FOR THE TREATMENT OF HUMANS AND ANIMALS | 2017 |
|
RU2758387C2 |
USE OF MICROBIAL COMMUNITIES FOR TREATING HUMANS AND ANIMALS | 2017 |
|
RU2823233C2 |
METHOD FOR ASSESSING INTESTINAL EPITHELIAL BARRIER PERMEABILITY IN PATIENTS RECEIVING HEMODIALYSIS TREATMENT | 2023 |
|
RU2817667C1 |
METHOD OF ISOLATING AND PRESERVING TOTAL INTESTINAL MICROBIOTA FOR TRANSPLANTATION | 2019 |
|
RU2727444C1 |
METHOD FOR CORRECTION OF COMPOSITION OF INTESTINAL MICROFLORA IN CHILDREN | 2022 |
|
RU2801611C1 |
METHOD FOR DETERMINING RESPONSE OF A PATIENT DIAGNOSED WITH SKIN MELANOMA TO ANTI-PD1-THERAPY | 2020 |
|
RU2771080C2 |
NUTRITIONAL COMPOSITIONS AND INFANT FORMULAS CONTAINING A MIXTURE OF OLIGOSACCHARIDES AND OPTIONAL BIFIDOBACTERIUM LACTIS FOR PREVENTION, TREATMENT OR REDUCTION OF THE SEVERITY OF NON-ROTAVIRUS RELATED DIARRHEA | 2017 |
|
RU2748279C2 |
Authors
Dates
2024-03-29—Published
2019-07-19—Filed